China, Vietnam set for first joint army drills as US trade war draws neighbours closer
In a statement posted on its website on Sunday, the ministry announced that the joint exercise would be held this month in southern China's Guangxi Zhuang autonomous region, which borders Vietnam.
Military ties between the Communist Party-led neighbours have deepened in recent months despite territorial disputes, as the
close economic partners seek ways to navigate the
US tariff war. The two sides have long carried out joint naval and land border patrols, but the coming exercise would be the first such exchange between their armies.
'This is the first joint army drill between China and Vietnam, with the theme of 'joint border patrol training',' the Chinese Ministry of Defence statement said.
The exercise would 'further deepen practical cooperation between the two militaries', it added.
On the economic front, China is Vietnam's largest trading partner and a critical supplier for its manufacturing sector. Chinese President Xi Jinping visited Vietnam in April, days after the escalation of the US tariff war, where he called on the Asian neighbours to cooperate to 'fight unilateral bullying'.
Closer defence cooperation this year – which marks the 75th anniversary of diplomatic ties – has included the Chinese military's first-ever appearance at Vietnam's annual celebration of the fall of Saigon.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTHK
32 minutes ago
- RTHK
Chinese AI firms play it smart amid US tech curbs
Chinese AI firms play it smart amid US tech curbs Digital AI glasses are the focus at a Rokid booth at the World Artificial Intelligence Conference in Shanghai. Photo: AFP China's artificial intelligence companies have announced two new industry alliances, aiming to develop a domestic ecosystem to reduce dependence on foreign tech as they seek to cope with US export restrictions on advanced Nvidia chipsets. The announcements were timed to coincide with the three-day World Artificial Intelligence Conference in Shanghai ending on Monday and came on the same day that the Financial Times reported that the United States has paused curbs on tech exports to China to avoid disrupting trade talks with Beijing and support President Donald Trump's efforts to secure a meeting with President Xi Jinping this year. The conference also showcased a slew of new products, such as an AI computing system from Huawei that experts believe rivals Nvidia's most advanced offering, as well as consumer-friendly products such as several kinds of digital AI glasses. The "Model-Chip Ecosystem Innovation Alliance" brings together Chinese developers of large language models (LLMs) and AI chip manufacturers. "This is an innovative ecosystem that connects the complete technology chain from chips to models to infrastructure," said Zhao Lidong, CEO of Enflame, one of the participating chipmakers. Other manufacturers of graphics processing units (GPUs) in the alliance include Huawei, Biren, and Moore Threads, which have been hit by US sanctions that block them from purchasing advanced tech made with US know-how. The alliance was announced by StepFun, an LLM developer. A second alliance, the Shanghai General Chamber of Commerce AI Committee, aims to "promote the deep integration of AI technology and industrial transformation". Participants include SenseTime, also sanctioned by the US and which has pivoted from facial recognition technology to LLMs. Others are StepFun and another LLM developer, MiniMax, as well as chipmakers Metax and Iluvatar CoreX. One of the most talked about products at the conference was Huawei's CloudMatrix 384 which incorporates 384 of its latest 910C chips and outperforms Nvidia's GB200 NVL72 on some metrics, according to US research firm SemiAnalysis. Huawei's system design capabilities have meant that it has been able to use more chips and system-level innovations to compensate for weaker individual chip performance, SemiAnalysis said. At least six other Chinese computing firms showcased similar "clustering" chip technology. Metax demonstrated an AI supernode featuring 128 C550 chips designed to support large-scale liquid-cooled data centre requirements. Other events included Tencent's unveiling of its open-source Hunyuan3D World Model 1.0, which the company said enables users to generate interactive 3D environments through text or image prompts. Baidu announced what it said was next-generation "digital human" technology that helps businesses to create virtual livestreamers. It features "cloning technology" that can replicate a human's voice, tone and body language from just 10 minutes of sample footage. Alibaba was among those announcing AI glasses. Its Quark AI Glasses are powered by its Qwen AI model and are due to be released in China by the end of 2025. They will allow users to access the tech giant's map service for easy navigating and to use Alipay by scanning QR codes with voice commands. (Reuters)
South China Morning Post
32 minutes ago
- South China Morning Post
Why some Chinese students are skipping elite universities amid job market fears
After underperforming in China's national college entrance exam in June, Lu Jie was accepted into a computer science and technology programme earlier this month at a lesser-known polytechnic university in central China's Hunan province. 'Good schools had too many applicants for this major, so I had to choose a lower-ranked one to pursue it,' Lu said. The results for the exam, better known as the gaokao , have been released over the past two weeks – marking a life-changing moment for students like Lu. Now more than ever, students are opting for majors with strong job prospects over prestigious universities. A focus on immediate employability and job security is eclipsing long-term aspirations and personal interests. Driving this trend is a growing oversupply of college graduates , intensifying competition in the job market amid a challenging economic climate. Computer science has long been a highly popular major, Lu said, but the rise of artificial intelligence (AI) – widely expected to create new job opportunities – has fuelled even greater demand over the past couple of years.
South China Morning Post
2 hours ago
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. Advertisement The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRD-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their product portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The corporate flag of GlaxoSmithKline (GSK) next to a Chinese national flag outside a GlaxoSmithKline office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. Advertisement 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.
